During a meeting in September 2024, the European Medicines Agency (EMA) approved the use of Penbraya, a pentavalent meningococcal vaccine by Pfizer, to protect individuals from invasive meningococcal disease caused by Neisseria meningitidis. The vaccine contains components from Trumenba and Nimenrix to protect against the five most common meningococcal serogroups. A Phase 3 trial showed that Penbraya was safe, well-tolerated, and produced robust immune responses. The EMA also approved updates to Spikevax and Comirnaty, mRNA vaccines by Moderna and Pfizer, respectively, to target specific SARS-CoV-2 variants for the 2024/2025 vaccination campaign recommended by the EMA Emergency Task Force.
Source link
EU OKs Meningococcal Disease Vaccine
